Literature DB >> 30451116

Cucurbitacins as Anticancer Agents: A Patent Review.

Hidayat Hussain1, Ivan R Green2, Muhammad Saleem3, Khanzadi F Khattak4, Muhammad Irshad5, Maroof Ali6.   

Abstract

BACKGROUND: Cucurbitacins belong to a group of tetracyclic triterpenoids that display a wide range of biological effects. In the past, numerous cucurbitacins have been isolated from natural sources and many active compounds have been synthesized using the privileged scaffold in order to enhance its cytotoxic effects.
OBJECTIVE: This review covers patents on the therapeutic effects of natural cucurbitacins and their synthetic analogs published during the past decade. By far, the majority of patents published are related to cancer and Structure-Activity Relationships (SAR) of these compounds are included to lend gravitas to this important class of natural products.
METHODS: The date about the published patents was downloaded via online open access patent databases.
RESULTS: Cucurbitacins display significant cytotoxic properties, in particular cucurbitacins B and D which possess very potent effects towards a number of cancer cells. Numerous cucurbitacins isolated from natural sources have been derivatized through chemical modification at the C(2)-OH and C(25)- OH groups. Most importantly, an acyl ester of the C(25)-OH and, iso-propyl, n-propyl and ethyl ether groups of the C(2)-OH demonstrated the most increased cytotoxic activity.
CONCLUSION: The significant cytotoxic effects of natural and semi-synthetic cucurbitacins make them attractive as new drug candidates. Moreover, cucurbitacins have the capability to form conjugates with other anticancer drugs which will synergistically enhance their anticancer effects. The authors believe that in order to get lead compounds, there should be a greater focus on the synthesis of homodimers, heterodimers, and halo derivatives of cucurbitacins. In the opinion of the authors the analysis of the published patents on the cucurbitacins indicates that these compounds can be developed into a regimen to treat a wide spectrum of cancers. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Anticancer; cucurbitaceae; cucurbitacins; in vitro; in vivo; plants.

Mesh:

Substances:

Year:  2019        PMID: 30451116     DOI: 10.2174/1574892813666181119123035

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN: 1574-8928            Impact factor:   4.169


  6 in total

Review 1.  Use of cucurbitacins for lung cancer research and therapy.

Authors:  Min Liu; Qijia Yan; Bi Peng; Yuan Cai; Shuangshuang Zeng; Zhijie Xu; Yuanliang Yan; Zhicheng Gong
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-06       Impact factor: 3.333

Review 2.  Phytochemicals for the Prevention and Treatment of Renal Cell Carcinoma: Preclinical and Clinical Evidence and Molecular Mechanisms.

Authors:  Essa M Bajalia; Farah B Azzouz; Danielle A Chism; Derrek M Giansiracusa; Carina G Wong; Kristina N Plaskett; Anupam Bishayee
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

3.  PLGA/β-TCP composite scaffold incorporating cucurbitacin B promotes bone regeneration by inducing angiogenesis.

Authors:  Wen-Xiang Cheng; Yan-Zhi Liu; Xiang-Bo Meng; Zheng-Tan Zheng; Ling-Li Li; Li-Qing Ke; Ling Li; Cui-Shan Huang; Guo-Yuan Zhu; Hu-Dan Pan; Ling Qin; Xin-Luan Wang; Peng Zhang
Journal:  J Orthop Translat       Date:  2021-11-01       Impact factor: 5.191

4.  Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in vitro.

Authors:  Dongchao Xu; Hongzhang Shen; Mengyao Tian; Wangyang Chen; Xiaofeng Zhang
Journal:  J Cancer       Date:  2022-03-28       Impact factor: 4.478

Review 5.  STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Sima Orouei; Vahideh Zarrin; Ebrahim Rahmani Moghadam; Amirhossein Zabolian; Shima Mohammadi; Kiavash Hushmandi; Yashar Gharehaghajlou; Pooyan Makvandi; Masoud Najafi; Reza Mohammadinejad
Journal:  Biology (Basel)       Date:  2020-06-12

6.  Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.

Authors:  Xiaoli Wang; Hua Li; Dong Li; Yudi Bai; Yao Zhang; Xue Yan; Jin Li; Ri Zhao; Jiahui Liu; Wei Liu; Maolin Shi; Cheng Xu; Tai Yang; Tao Zhang
Journal:  FEBS Open Bio       Date:  2020-11-27       Impact factor: 2.792

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.